0000919574-18-007840.txt : 20181203 0000919574-18-007840.hdr.sgml : 20181203 20181203165051 ACCESSION NUMBER: 0000919574-18-007840 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20181203 DATE AS OF CHANGE: 20181203 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NOVELION THERAPEUTICS INC. CENTRAL INDEX KEY: 0000827809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-43381 FILM NUMBER: 181214497 BUSINESS ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 BUSINESS PHONE: (877) 764-3131 MAIL ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 FORMER COMPANY: FORMER CONFORMED NAME: QLT INC/BC DATE OF NAME CHANGE: 20000608 FORMER COMPANY: FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC DATE OF NAME CHANGE: 19960618 FORMER COMPANY: FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC DATE OF NAME CHANGE: 19941201 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Value Capital, LLC CENTRAL INDEX KEY: 0001458461 IRS NUMBER: 320251223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 50 TICE BLVD STREET 2: SUITE 140 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 212-488-5411 MAIL ADDRESS: STREET 1: 50 TICE BLVD STREET 2: SUITE 140 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 SC 13D/A 1 d8109015_13d-a.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

Under The Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Novelion Therapeutics Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)

 

67001K202
(CUSIP Number)

 

Joseph P. Riccardo

c/o Healthcare Value Capital, LLC

50 Tice Blvd, Suite 140

Woodcliff Lake, New Jersey 07677

(Name, Address and Telephone Number of Person Authorized to Receive

Notices and Communications)

 

December 3, 2018
(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13D-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [X].
 
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
   
*   The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


 

 

CUSIP No. 67001K202    

 

1. NAME OF REPORTING PERSONS  
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
     
  Healthcare Value Capital, LLC  

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) [__]
    (b) [X]

 

3. SEC USE ONLY

 

4. SOURCE OF FUNDS*  
     
  AF  

 

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
     
     

 

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
     
  Delaware  

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     

 

7. SOLE VOTING POWER  
     
  0  

 

8. SHARED VOTING POWER  
     
  1,800,000  

 

9. SOLE DISPOSITIVE POWER
     
  0  

 

10. SHARED DISPOSITIVE POWER   [_]
     
  1,800,000  

 

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
 

PERSON

 

  
  1,800,000  

 

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
  CERTAIN SHARES*  
     

 

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
     

  9.5%  

 

14. TYPE OF REPORTING PERSON*  
     
  IA, OO  


 

 

CUSIP No. 67001K202    

 

1. NAME OF REPORTING PERSONS  
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
     
  Healthcare Value Capital General Partner, LLC  

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) [__]
    (b) [X]

 

3. SEC USE ONLY

 

4. SOURCE OF FUNDS*  
     
  AF  

 

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
     
     

 

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
     
  United States of America  

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     

 

7. SOLE VOTING POWER  
     
  0  

 

8. SHARED VOTING POWER  
     
  1,800,000  

 

9. SOLE DISPOSITIVE POWER
     
  0  

 

10. SHARED DISPOSITIVE POWER   [_]
     
  1,800,000  

 

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
 

PERSON

 

  
  1,800,000  

 

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
  CERTAIN SHARES*  
     

 

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
     

 

  9.5%  

 

14. TYPE OF REPORTING PERSON*  
     
  OO  


 

 

CUSIP No. 67001K202  

 

1. NAME OF REPORTING PERSONS  
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
     
  Healthcare Value Partners, L.P.  

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) [__]
    (b) [X]

 

3. SEC USE ONLY

 

4. SOURCE OF FUNDS*  
     
  WC  

 

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
     
     

 

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
     
  Delaware  

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     

 

7. SOLE VOTING POWER  
     
  0  

 

8. SHARED VOTING POWER  
     
  1,800,000  

 

9. SOLE DISPOSITIVE POWER
     
  0  

 

10. SHARED DISPOSITIVE POWER   [_]
     
  1,800,000  

 

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
 

PERSON

 

  
  1,800,000  

 

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
  CERTAIN SHARES*  
     

 

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
     

 

  9.5%  

 

14. TYPE OF REPORTING PERSON*  
     
  PN  

 

 

 

  

CUSIP No. 67001K202    

 

1. NAME OF REPORTING PERSONS  
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
     
  Joseph P. Riccardo  

  

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) [__]
    (b) [X]

 

3. SEC USE ONLY  
     

 

4. SOURCE OF FUNDS*  
     
  AF  

  

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
     
     

 

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
     
  United States of America  

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     

 

7. SOLE VOTING POWER  
     
  0  

 

8. SHARED VOTING POWER  
     
  1,800,000  

 

9. SOLE DISPOSITIVE POWER
     
  0  

 

10. SHARED DISPOSITIVE POWER   [_]
     
  1,800,000  

 

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
 

PERSON

 

  
  1,800,000  

 

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
  CERTAIN SHARES*  
     

 

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
     
  9.5%  

 

14. TYPE OF REPORTING PERSON*  
     
     
  IN, HC  

 

 

 

 

CUSIP No. 67001K202  

 

Item 1. Security and Issuer.

 

  The name of the issuer is Novelion Therapeutics Inc. (the "Issuer").  The address of the Issuer's principal executive offices is c/o Norton Rose Fulbright, 1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada.  This Schedule 13D relates to the Issuer's Common Stock, no par value (the "Shares").

 

Item 2. Identity and Background.

 

(a-c, f) This Schedule 13D/A is being filed jointly by Healthcare Value Capital, LLC, a Delaware limited liability company, Healthcare Value Capital General Partner, LLC, a Delaware limited liability company, Healthcare Value Partners, L.P., a Delaware limited partnership, and Joseph P. Riccardo, a United States citizen (the “Reporting Persons”). Mr. Riccardo is the managing member of each of Healthcare Value Capital, LLC and Healthcare Value Capital General Partner, LLC.  The principal business address of the Reporting Persons is 50 Tice Blvd, Suite 140, Woodcliff Lake, New Jersey 07677.

(d) There were no criminal proceedings during the last five years referred to in Item 2(d), in which the Reporting Persons or their executive officers were convicted (excluding traffic violations or similar misdemeanors).

(e)  None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

 

No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

Item 4. Purpose of Transaction.

 

Item 4 is hereby amended and supplemented with the following:

On December 3, 2018, Healthcare Value Capital, LLC, on behalf of Healthcare Value Partners, L.P., sent a letter to the Board of Directors of the Issuer which is filed as Exhibit 99.2 hereto and incorporated by reference into this Item 4 as if restated in full herein. 

 

 

 

Item 5. Interest in Securities of the Issuer.

 

(a-e)  As of the date hereof, Healthcare Value Capital, LLC may be deemed to be the beneficial owner of 1,800,000 Shares (9.5%) of the Issuer, based upon the 18,932,230 Shares outstanding as of November 5, 2018, according to the Issuer.  Healthcare Value Capital, LLC has the sole power to vote or direct the vote of 0 Shares, Healthcare Value Capital, LLC has the shared power to vote or direct the vote of 1,800,000 Shares, Healthcare Value Capital, LLC has the sole power to dispose or direct the disposition of 0 Shares and Healthcare Value Capital, LLC has the shared power to dispose or direct the disposition of 1,800,000 Shares to which this filing relates.

The Healthcare Value Capital General Partner, LLC may be deemed to be the beneficial owner of 1,800,000 Shares (9.5%) of the Issuer, based upon the 18,932,230 Shares outstanding as of November 5, 2018, according to the Issuer. The Healthcare Value Capital General Partner, LLC has the sole power to vote or direct the vote of 0 Shares, the Healthcare Value Capital General Partner, LLC has the shared power to vote or direct the vote of 1,800,000 Shares, the Healthcare Value Capital General Partner, LLC has the sole power to dispose or direct the disposition of 0 Shares and the Healthcare Value Capital General Partner, LLC has the shared power to dispose or direct the disposition of 1,800,000 Shares to which this filing relates. 

Healthcare Value Partners, L.P. may be deemed to be the beneficial owner of 1,800,000 Shares (9.5%) of the Issuer, based upon the 18,932,230 Shares outstanding as of November 5, 2018, according to the Issuer.  Healthcare Value Partners, L.P. has the sole power to vote or direct the vote of 0 Shares, Healthcare Value Partners, L.P. has the shared power to vote or direct the vote of 1,800,000 Shares, Healthcare Value Partners, L.P. has the sole power to dispose or direct the disposition of 0 Shares and Healthcare Value Partners, L.P. has the shared power to dispose or direct the disposition of 1,800,000 Shares to which this filing relates.

Mr. Riccardo may be deemed to be the beneficial owner of 1,800,000 Shares (9.5%) of the Issuer, based upon the 18,932,230 Shares outstanding as of November 5, 2018, according to the Issuer.  Mr. Riccardo has the sole power to vote or direct the vote of 0 Shares, Mr. Riccardo has the shared power to vote or direct the vote of 1,800,000 Shares, Mr. Riccardo has the sole power to dispose or direct the disposition of 0 Shares and Mr. Riccardo has the shared power to dispose or direct the disposition of 1,800,000 Shares to which this filing relates.

The transactions in the Shares by the Reporting Persons in the past 60 days are set forth in Exhibit 99.3. All transactions were conducted in the open market.

The Reporting Persons specifically disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
  to Securities of the Issuer.

 

Not applicable.

Item 7. Material to be Filed as Exhibits.

 

 

Exhibit

99.1       Joint Filing Statement

99.2       Letter to the Board of Directors of the Issuer

99.3       Schedule of Transactions in the Shares by the Reporting Persons

 

 

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

  December 3, 2018
  (Date)
   
   
  Healthcare Value Capital, LLC*
  By:   /s/ Joseph P. Riccardo
  Joseph P. Riccardo
 

Managing Member

 

  Healthcare Value Capital General Partner, LLC*
  By:   /s/ Joseph P. Riccardo
  Joseph P. Riccardo
 

Managing Member

 

  Healthcare Value Partners, L.P.*
  By Healthcare Value Capital General Partner, LLC, its general partner
  By: /s/ Joseph P. Riccardo
  Joseph P. Riccardo
 

 

/s/ Joseph P. Riccardo*

  Joseph P. Riccardo
   

 

* This Reporting Person disclaims beneficial ownership in the Common Stock, except to the extent of his or its pecuniary interest therein.

 

Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).


 

 

Exhibit 99.1

AGREEMENT

The undersigned agree that this Schedule 13D Amendment No. 1 dated December 3, 2018 relating to the Common Stock of Novelion Therapeutics Inc. shall be filed on behalf of the undersigned.

Healthcare Value Capital, LLC  
By:   /s/ Joseph P. Riccardo  
Joseph P. Riccardo  

Managing Member

 

  
Healthcare Value Capital General Partner, LLC  
By:   /s/ Joseph P. Riccardo  
Joseph P. Riccardo  

Managing Member

 

  
Healthcare Value Partners, L.P.  
By Healthcare Value Capital General Partner, LLC, its general partner  
By: /s/ Joseph P. Riccardo  
Joseph P. Riccardo  

Managing Member

 

 

/s/ Joseph P. Riccardo

  

Joseph P. Riccardo

 

 

 

 

 

 

 

Exhibit 99.2

December 3, 2018

 

 

Board of Directors

Novelion Therapeutics Inc.

c/o Norton Rose Fulbright

1800 - 510 West Georgia Street

Vancouver, BC V6B 0M3

Canada

 

Dear Ladies and Gentlemen:

 

Our fund, Healthcare Value Partners, L.P., has been a significant and supportive shareholder of Novelion Therapeutics Inc. and its affiliates ("Novelion") and its predecessor QLT Inc. for nearly eight years. We are among the largest owners of common stock, with 1.8 million shares held by our fund or 9.52% of currently outstanding shares, and we take pride in being value-added, long-term partners of Novelion and our fellow shareholders.

 

We have worked hard to provide practical, constructive advice to you and your various management teams, during the term of our ownership, based on our extensive knowledge of the industry and similarly situated issuers. Our principals have been actively engaged in advising and sponsoring drug and other healthcare companies for more than 40 years.

 

Your and your predecessors' oversight of the core commercial business, which is contained in your subsidiary Aegerion Pharmaceuticals, Inc. (“Aegerion”), has been consistently poor spanning many years. You have allowed Novelion's costs, in particular SG&A and R&D, to run completely out of control, far exceeding all reasonable benchmarks and control limits for emerging growth biotech firms.

 

For example, through the first 9 months of 2018, SG&A expense was $65.8 million, or 73% of revenue. This is in sharp contrast to pharmaceutical industry averages in the 20 – 30% range. Similarly, R&D expense during this same period was $31.1 million, or 35% of revenue. This compares to industry averages in the 10 – 20% range and is especially indefensible given the poor productivity in advancing existing leads and the void of any apparent new product candidates in the pipeline.

 

 

 

 

These enormously high spending levels, of course, led to the endless realization of net operating losses and the recurring need to raise multiple stop-gap financings in order to avoid insolvency and a disruption of the core Juxtapid and Myalept franchises. Novelion has realized more than $135 million of cumulative cash operating losses since the merger with Aegerion in November 2016, despite having core businesses that yield very high gross margins. Chronic mismanagement and poor oversight by the Board have induced severe financial distress, which has irreparably harmed shareholder confidence as evidenced by the progressive collapse of the stock price.

 

Further, in the face of extreme projected cash burn rates, you inexplicably waited until 3Q18 to attempt to normalize this unsustainable cost structure. The prior restructurings of 1Q16, 3Q16, 1Q-2Q17, and 1Q18 were wholly inadequate. The stop-gap bridge financings, all expensive and dilutive to equity claims, have simply created runways to the next crisis.

 

You have now taken the additional step of installing Novelion’s General Counsel, Benjamin Harshbarger, as the interim CEO, replacing Jeffrey Hackman. After several discussions with Mr. Hackman, we believed he was motivated and well-positioned, with the advice of restructuring expert AlixPartners, to assure a transition, however difficult, to a new state and capital structure that would have permitted Novelion to remain independent and build its business without the cost and distraction of financial distress.

 

By putting a lawyer, and not an operations expert, in charge of Novelion, we are concerned you are sending a clear signal that you intend to sell or even liquidate Novelion, perhaps at an extreme discount to fair value in order to repay principal to the creditors that have funded a bridge loan and a substantial portion of a convertible bond instrument. This signal was further reinforced by the recent 8-K filing on November 26, 2018, describing a “retention plan” for key executives through a “transaction event”.

 

You have indicated that Novelion will likely generate $120 million in cash gross profit from revenue of $145 – $160 million in 2019 and that further restructuring will enable Novelion to become cash flow positive in 2Q19. At present, the universe of publicly-traded orphan drug companies trades at an average ratio of enterprise value to 2019E (projected) gross profit of 8.7x. This multiple applied to Novelion’s expected 2019 gross profit implies a fair value of $34 per fully-diluted common share. Large-capitalization firms in the pharmaceutical and biotech sectors, both of which are growing more slowly than Novelion, trade at average ratios of enterprise value to 2019E (projected) revenue of 4.0x and 6.0x, respectively. Applying those multiples to Novelion’s 2019 revenue guidance suggests a fair value range of $10 – $30 per share.

 

(see Exhibit A for peer group asset pricing multiples)

 

 

 

Relative to its peers, Novelion’s inferred enterprise value is in the range of $600 – $1,200 million. As such, we believe the pro forma intrinsic value of Novelion, as a standalone entity (without a change of control), far exceeds $600 million under distressed conditions.

 

You were each elected and are paid by the owners of Novelion to govern vigilantly on the shareholders’ behalf and hold management and fellow directors accountable. Your primary obligation, as overseers and fiduciaries, is to protect the shareholders, whose risk capital, in part, has permitted Novelion to exist and endure.

 

We fully expect you to represent us as shareholders and protect our interests during this ongoing crisis and ensure an outcome that maximizes the value of our economic claim. Notably, we expect you to faithfully and thoroughly explore all strategic alternatives and not simply choose the most expedient solution for the debt-holders at the expense of the equity-holders. In so doing, you will preserve an important, life-saving business that serves severely-ill patients around the world as well as the claims of all other stakeholders.

 

We would welcome the opportunity to meet with you and management to discuss our thoughts on an immediate program to decisively and permanently normalize costs as well as the relative merits, timing, and terms for the strategic alternatives available to Novelion.

 

 

 

Sincerely,

 

Joseph P. Riccardo
Managing Member

Healthcare Value Capital, LLC

 

 

 

 

Exhibit A

 

Novelion Therapeutics Inc.

 

Valuation Peer Group Summary

Publicly-Traded Companies

 

(priced as of 2018-11-27)

 

 

 

 

 

 

Exhibit 99.3

 

SCHEDULE OF TRANSACTIONS IN THE SHARES BY THE REPORTING PERSONS

Schedule of Transactions in Common Stock by Healthcare Value Capital, LLC and Healthcare Value Capital General Partner, LLC (on behalf of Healthcare Value Partners, L.P. for which they act as investment manager and general partner, respectively)

Date   Purchase/Sale   Price   Number of Shares
Acquired (Disposed)
09/28/2018   Sale   $3.03   (301,900.00)
10/02/2018   Sale   $2.66   (3,014.00)
10/03/2018   Sale   $2.41   (20,142.00)
10/03/2018   Sale   $2.44   (10,000.00)
10/04/2018   Sale   $2.14   (9,100.00)
10/05/2018   Sale   $2.06   (68,635.00)
10/10/2018   Sale   $2.01   (7,300.00)
11/08/2018   Purchase   $1.32   400,000.00
11/08/2018   Purchase   $1.29   235,200.00
11/09/2018   Purchase   $1.72   71,504.00
11/14/2018   Purchase   $1.05   100,000.00
11/15/2018   Purchase   $1.10   100,000.00

 

 

 

 GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end